Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 24 January 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has announced the release of a new guidance document intended for both its staff and the medical device industry pertaining to the issuance of humanitarian use device (HUD) designations for devices intended to treat rare diseases or conditions.
Much like orphan drugs, which are intended to treat conditions that affect fewer than 200,000 people in the US, HUD designations are given to medical devices that are intended to cure, treat or diagnose a condition that is found in fewer than 4,000 individuals in the US per year. As with its pharmaceutical counterpart, the HUD designation affords sponsors faster review time and additional support from FDA reviewers.
The designation is separate from the approval or non-approval of the application itself, known as a Humanitarian Device Exemption (HDE) application, which is similar in nature to a Premarket Approval (PMA) application in that it must prove that it is safe for use in humans. It does not, however, need to meet standards of efficacy, which a PMA application must prove.
In December 2011, FDA released a draft guidance on the topic, inviting comment from industry and those seeking the HUD designation.
Those designations need to contain certain information not ordinarily found in other types of applications, including a statement indicating the sponsor is seeking a HUD designation, a description of the rare disease, demonstration of the medical plausibility of the disease as a medically important subset, and proof that the disease affects fewer than 4,000 individuals in the US.
The population estimate is particularly important, as a population of more than 4,000 will automatically disqualify the device from being able to obtain a HUD designation and thus the ability to obtain approval using an HDE application.
There are two distinctions that FDA said it wanted manufacturers to understand clearly: prevalence and incidence. The former refers to the total number of patients with a given disease at a given point in time, and is sometimes referred to as point prevalence. The latter term refers to the number of new patients, and is sometimes referred to as annual incidence. FDA's HUD designation is based upon incidence, not prevalence.
Certain devices, such as diagnostic devices, can also run into some tricky interpretations of the HUD designation's legislative wording. A diagnostic device that is intended to screen all newborn children to look for a disease that affects fewer than 4,000 individuals would not be eligible for a HUD designation, while one only intended for use in those 4,000 individuals would be, FDA said.
The "medically plausible" subset is also important. A manufacturer would, for example, be hard-pressed to take an annual incidence of 8,000 affected individuals-for the sake of argument, equally divided into men and women-and claim that its product only treated the men in order to obtain a HUD designation.
"Medically plausible subset" or "orphan subset" is a regulatory term used to describe a situation where the incidence of a disease or condition is 4,000 or more patients per year in the US, but because a product can only be used in a smaller subset of people with the common disease or condition, it qualifies for HUD designation," FDA explained. "A medically plausible subset must be based on some feature of the device (i.e., mode of action, adverse event profile, etc.) that actually precludes its use in the treatment of patients outside the smaller subset of individuals."
"There should be justification as to why the device could not be used to treat or diagnose all remaining persons with the disease or condition," FDA added.
FDA said its final guidance reflects some "minor revisions to improve clarity," but is otherwise the same as the December 2011 draft guidance, Humanitarian use Device Designations: Guidance for Industry and Staff.
Tags: HDE, HUD
Regulatory Focus newsletters
All the biggest regulatory news and happenings.